DDInter204 DDInter1658
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Bicalutamide {u} (Compound) treats {v} (Disease) prostate cancer
Bicalutamide {u} (Compound) binds {v} (Gene) AR
Bicalutamide {u} (Compound) upregulates {v} (Gene) USP6NL
Bicalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Bicalutamide {u} (Compound) downregulates {v} (Gene) TUBB6
Bicalutamide {u} (Compound) causes {v} (Side Effect) Melaena
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Bicalutamide (Compound) resembles Enzalutamide (Compound)
Bicalutamide (Compound) treats prostate cancer (Disease)
Bicalutamide (Compound) binds AR (Gene)
Bicalutamide (Compound) upregulates USP6NL (Gene)
Bicalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class)
Bicalutamide (Compound) downregulates TUBB6 (Gene)
Bicalutamide (Compound) causes Melaena (Side Effect)
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine